Drug or intervention
insulin glargine Clinical Trials
Studies that test insulin glargine, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 17Gestational Diabetes Mellitus, Pregnancy, High Risk
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational…
- Trial name
- DECIDE (NCT06445946)
- Testing
- Metformin, Insulin
- Where
- 26 sites in United States
- Volunteers
- 1,572 people
- Sponsor
- Ohio State University
Type 2 Diabetes, Cardiovascular Risk
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already…
- Trial name
- AMBITION 7 (NCT07797335)
- Testing
- Zenagamtide, Insulin glargine U-100
- Where
- 330 sites in United States, Argentina and 14 more
- Volunteers
- 1,778 people
- Sponsor
- Novo Nordisk A/S
Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial
This exploratory randomized controlled trial evaluates whether a CGM-guided temporary patch pump (CareLevo CSII) reduces glucocorticoid-induced hyperglycemia (GIH) compared to a Lantus-based basal-bolus injection (MDI) regimen in…
- Trial name
- SHIP (NCT07652528)
- Testing
- CareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp)
- Volunteers
- 50 people
- Sponsor
- Hallym University
Type 2 Diabetes
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT).
- Trial name
- NCT07307235
- Testing
- iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
- Where
- 24 sites in China
- Volunteers
- 1,316 people
- Sponsor
- Shanghai Zhongshan Hospital
Pregestational Diabetes, Pregnancy
Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management
The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients.
- Trial name
- NCT07224893
- Testing
- Use of insulin glargine once daily, Use of insulin glargine twice daily
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Eastern Virginia Medical School
Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes
Objectives: The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure…
- Trial name
- ASCEND001 (NCT07568574)
- Testing
- Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate
- Where
- United Arab Emirates
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Enhanced Emirates Limited
Diabetes in Pregnancy, Gestational Diabetes
Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)
The goal of this clinical trial is to see if diabetes in pregnancy can be treated with once daily dosing of insulin instead of once daily dosing plus insulin with meals. The main question this study aims to answer is: 1.
- Trial name
- SUGAR (NCT07171684)
- Testing
- Insulin glargine alone, Insulin glargine + insulin lispro
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- Rutgers, The State University of New Jersey
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Type 2 Diabetes
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Failure of oral antidiabetic drugs (OADs) is a frequent challenge in patients with type 2 diabetes mellitus (T2DM), and inadequate long-term glycemic control substantially increases the risk of diabetic complications.
- Trial name
- NCT07173712
- Testing
- CSII, Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin Degludec and Insulin Aspart Injection
- Volunteers
- 324 people
- Sponsor
- Yanbing Li
Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects.
- Conditions
- Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes
- Trial name
- NCT07117240
- Testing
- lixisenatide + glargine, Intensive insulin therapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Completed, with results posted
All 262Healthy Participants
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus®, and…
- Trial name
- NCT06627478
- Testing
- NKF-INS(G), US-Lantus®, EU-Lantus®
- Where
- South Africa
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Xentria, Inc.
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or…
- Trial name
- ACHIEVE-5 (NCT06109311)
- Testing
- Orforglipron
- Where
- 70 sites in United States, Brazil and 4 more
- Volunteers
- 546 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.
- Trial name
- NCT06370715
- Testing
- Insulin Lispro-aabc, Insulin Glargine
- Where
- 12 sites in India
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Diabetes, Type 2
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes.
- Trial name
- NCT06340854
- Testing
- Insulin icodec, Insulin glargine
- Where
- 83 sites in United States, Bulgaria and 7 more
- Volunteers
- 412 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily.
- Trial name
- ONWARDS 5 (NCT04760626)
- Testing
- Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec
- Where
- 311 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,085 people
- Sponsor
- Novo Nordisk A/S